You are here

AKUT İSKEMİK STROKTA SERUM NÖRON-SPESİFİK ENOLAZ’IN PROGNOSTİK DEĞERİ

Journal Name:

Publication Year:

Keywords (Original Language):

Abstract (2. Language): 
The aim of the study was to see whether the serum neuron specific enolase (NSE) levels, as a noninvasive technique could be utilized to determine the morbidity at early stage after acute ischemic stroke. Design.- In the present study, 40 patients with acute ischemic stroke and 20 ages and gender matched volunteer were investigated. Serum NSE levels at 48th hours, fifth days, and tenth days were analyzed and simultaneous clinical status according to Scandinavian stroke scale was examined and infarct volumes at 48th hours were measured. Results and Conclusion.- There was a statistically significant difference in serum NSE values at 48th hours and fifth days of whole patient group (22,51±7.05 ng/ml, 13,1±4,76 ng/ml, respectively) compared to those of control group (8.54±2,58 ng/ml), ( p<0.001, p<0.01, respectively). However there was no statistically significant difference between the patients and controls at 10 days (p<0.01). So, it was thought that NSE had 94% sensitivity and 80% specifity for acute ischemic stroke. There were positive correlation among NSE levels and infarct volumes, and negative correlation among NSE levels and clinical status.
Abstract (Original Language): 
Bu çalışmanın amacı, akut iskemik strok sonrası morbiditenin erken dönemde belirlenmesinde serum Nöron Spesifik Enolaz (NSE) düzeyinin noninvazif bir yöntem olarak kulanılıp kullanılamayacağını araştırmaktır. Bu çalışmaya akut iskemik stroklu 40 hasta ve yaş ve cinsiyet özellikleri uyumlu 20 gönüllü alınmıştır. Çalışma grubunun strok sonrası 48. saat, 5. ve 10. günlerdeki serum NSE düzeyleri ile eş zamanlı Scandinavian Strok Skalası’na göre klinik durumları ve 48. saatteki infarkt volümleri belirlendi. Tüm hastaların 48. saatteki ve beşinci gündeki serum NSE değerleri ile (sırasıyla; 22,51± 7,05 ng/ml, 13,1±4,76 ng/ml) kontrol grubunun serum NSE değerleri (8,54±2,58 ng/ml) arasında istatistiksel olarak anlamlı fark bulundu (sırasıyla p<0.001, p<0.01). Onuncu gündeki serum NSE değerleri ile kontrol grubunun serum NSE değerleri arasında ise istatistiksel anlamlılık mevcut değildi (p>0.05). Serum NSE seviyeleri ile İnfarkt volümü arasında anlamlı pozitif ilişki, serum NSE değerleri ile klinik durum arasında ise anlamlı negatif ilişki gözlendi. NSE’nin akut stroklu hastalarda sensitivitesi %94 ve spesifitesi %80 olarak bulundu.
81-85

REFERENCES

References: 

1. Day INM, Thopson RJ. Levels of immunoreactive
aldolase C, creatine kinase-BB, neuronal and
nonneuronal enolase and 14-3-2 protein in circulating
human blood cells. Clin Chem Acta 1984; 136: 219-228.
2. Marangos PJ, Champbell IC, Godvin FK. Structural and
functional properties of neuron specific protein (NSP)
from rat, cat and human brain. J Neurcochem 1977; 28:
1097-1107.
3. Cunningham RT, Watt M, Winder J. Serum neuronespecific
enolase as an indicator of stroke volume. Eur J
Clin Invest 1996; 26: 298-303.
4. Cunningham RT, Young IS, Winder J. Serum neurone
specific enolase (NSE) levels as an indicator of neuronal
damage in patients with cerebral infarction. Eur J Clin
Invest 1991; 21: 497-500.
5. Martens P, Raabe A, Johnsson P. Serum S-100 and
neuron-specific enolase for prediction of regaining
consciousness after global cerebral ischemia. Stroke
1998; 29: 2363-2366.
6. Missler U, Wiesmann M, Friedrich C, Kaps M. S-100
Protein and neuron-specific enolase concentrations in
blood as indicators of infarction volume and prognosis in
acute ischemic stroke. Stroke 1997; 28: 1956-1960.
7. Stevens H, Jakobs C, de Jager AE, Cunningham RT, Korf
J. Neurone-specific enolase and N-acetyl-aspartate as
potential peripheral markers of ischemic stroke. Eur J
Clin Invest 1999; 29: 1 6-11.
8. Wunderlich MD, Ebert AD, Kratz T, Goertler M, Jost S,
Herrmann M. Early neurobehavioral outcome after stroke
is related to release of neurobiochemical markers of brain
damage. Stroke 1999; 30: 1190-1195.
9. Waltraud S, Harald K, Fritz S, Wilhelm B, Michael
Holzer. Time course of serum neuron-specific enolase
apredictor of neurological outcome in patients
resuscitated from cardiac arrest. Stroke 1999; 30: 1598-
1603.
10. Savory J,Brody JP. Measurements and diagnostic values
of CSF enzymes. Ann Clin Lab Sci 1979; 1: 69-79.
Nisan-Haziran 2003 İSKEMİK STROK, NÖRON-SPESİFİK ENOLAZ; BULUT VE ARK.
85
11. Williams LD, Marks V. Chemistry of the cerebrospinal
fluid in health and disease biochemistry in clinical
practice. London: William Heinman Medical Books
Limited. 1983: 445-465.
12. Steinberg R, Gueniau C, Scarna H, Keller A, Worcel M,
Pujol JF. Experimental brain ischemia: Neuron-specific
enolase level in cerebrospinal fluid as an index of
neuronal damage. J Neurochem 1984; 43: 19-24.
13. Cunnigham RT, Morrow JI, Johnston CF, Buchanan KD.
Neuron-specific enolase concentrations in patients with
neurological disorders. Clin Chim Acta 1994; 230: 117-
124.
14. De Giorgio CM, Correale JD, Gott PS. Serum neuronspecific
enolase in human status epilepticus. Neurology
1995; 45: 1134-1137.
15. Garcia-Alix A, Cabanas F, Pellicer A, Hernenz A, Stiris
TA, Quero J. Neuron-specific enolase and myelin basic
protein: Relationship of cerebrospinal fluid to the
neurologic condition of asphyxiated full-term infants.
Pediatrics 1994; 93: 234-240.
16. Nara T, Nozaki H, Nakae Y, Arai, T, Ohashi T. Neuronspecific
enolase in comatose children. AJDJ 1988; 142:
173-174
17. Hardemark HG, Ericsson N, Kotwica Z. S-100 and
neuron specific enolase in CSF after experimental
traumatic or focal ischemic brain damage. J Neurosurg
1989; 71: 727-731.
18. Hatfield RH, Mckernan RM. CSF neuron specific enolase
as a quantitative marker of neuronal damage in rat stroke
model. Brain Res 1992; 577: 249-252.
19. Fogel W, Krieger D, Veith M, Adams HP, Hund E.
Serum neuron specific enolase early predictor of outcome
after cardiac arrest. Crit Care Med 1997; 25: 1133-1138

Thank you for copying data from http://www.arastirmax.com